REFERENCES
- Sugiura S. Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 1978; 22: 9–35, [CSA]
- Ohno S, Char D H, Kimura S J, O'Connor G R. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1977; 83(5)735–740, [PUBMED], [INFOTRIEVE], [CSA]
- Snyder D A, Tessler H H. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1980; 90(1)69–75, [PUBMED], [INFOTRIEVE], [CSA]
- Chan C C. Relationship between sympathetic ophthalmia, phacoanaphylactic endophthalmitis and Vogt Koyanagi Harada disease. Ophthalmology 1998; 95(5)619–624, [CSA]
- Matsuda H, Sugiura S. Ultrastructural changes of the melanocyte in Vogt Koyanagi Harada syndrome and sympathetic ophthalmia. Jpn J Ophthalmol 1971; 15: 69–80, [CSA]
- Norose K, Yano A, Aosai F, et al. Immunologic analysis of cerebro-spinal fluid lymphocytes in Vogt Koyanagi Harada disease. Invest Ophthalmol Vis Sci 1990; 31: 1210–1216, [PUBMED], [INFOTRIEVE], [CSA]
- Sakamoto T, Murata T, Inomata H. Class II major histocompatibility complex on melanocytes of Vogt Koyanagi Harada disease. Arch Ophthalmol 1991; 109: 1270–1274, [PUBMED], [INFOTRIEVE], [CSA]
- Tagawa Y. Lymphocyte mediated cytotoxicity against melanocyte antigens in Vogt Koyanagi Harada syndrome. Jpn J Ophthalmol 1978; 22: 36–41, [CSA]
- Read R W, Rao N A, Cunningham E T. Vogt Koyanaga Harada disease. Curr Opin Ophthalmol. 2000; 11(6)437–442, [PUBMED], [INFOTRIEVE], [CSA]
- Shindo Y, Ohno S, Yamamoto T, et al. Complete association of the HLADRB1*04 and -DQB1*04 alleles with Vogt Koyanagi Harada's disease. Hum Immunol 1994; 39: 169–176, [PUBMED], [INFOTRIEVE], [CSA]
- Weisz J M, Holland G N, Roer L N, et al. Association between Vogt Koyanagi Harada syndrome and HLA DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmol. 1995; 102: 1012–1015, [CSA]
- Kim M H, Seong M C, Kwak N H, et al. Association of HLA with Vogt Koyanagi Harada syndrome in Koreans. Am J Ophthalmol 2000; 129: 173–177, [PUBMED], [INFOTRIEVE], [CSA]
- Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi R A, et al. Vogt Koyanagi Harada disease and HLA type in Italian patients. Am J Ophthalmol 1996; 122: 889–891, [PUBMED], [INFOTRIEVE], [CSA]
- Arellanes-Garcia L, Bautista N, Mora P, et al. HLA DR is strongly associated with Vogt Koyanagi Harada disease in Mexican Mestizo patients. Ocul Immunol Inflam 1998; 6: 93–100, [CSA]
- Zhao M, Jiang Y, Abrahams I W. Association of HLA antigens with Vogt Koyanagi Harada syndrome in a Han Chinese population. Arch Ophthalmol 1991; 109: 368–370, [PUBMED], [INFOTRIEVE], [CSA]
- Goldberg A C, Yamamoto J H, Chiarella J M, et al. HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt Koyanagi Harada disease. Hum Immunol 1998; 59: 183–188, [PUBMED], [INFOTRIEVE], [CSA]
- Riddington L, Hall A J, Tait B, et al. Vogt Koyanagi Harada syndrome in patients of Vietnamese ancestry. Aust NZ J Ophthalmol 1996; 24: 147–149, [CSA]
- Rubsamen P E, Gass J D. Vogt Koyanagi Harada Syndrome. Clinical course, therapy, and long-term visual outcome. Arch Opthalmol. May, 1991; 109(5)682–687, [CSA]
- Rathiam S R, Vijayalakshmi P, Cunningham E T, jr, et al. Vogt Koyanagi Harada syndrome in children. Ocul Immunol Inflam 1998; 6(3)155–161, [CSA]
- Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt Koyanagi Harada disease. Ophthalmologica 1990; 201(3)162–167, [PUBMED], [INFOTRIEVE], [CSA]
- Zhang M, Liu Q, Min H, Du H, Hu T. [Vogt Koyanagi Harada syndrome: glucocorticoid therapy and visual prognosis]. Zhonghua Yan Ke Za Zhi 2002; 38(4)200–203, [PUBMED], [INFOTRIEVE], [CSA]
- Biswas J, Rao N A. Management of intraocular inflammation. Retina, S J Ryan. Mosby-Year Book, St. Louis 1994; Vol. 2: 1061–1069
- Rao N A, Blackman H J, Franklin R M, et al. Intraocular inflammation and uveitis. Basic and clinical science course 1998–1999. American Academy of Ophthalmology, San Francisco 1998; 76–79
- Hayasaka S, Okabe H, Takahashi J. Systemic corticosteroid treatment in Vogt Koyanagi Harada disease. Graefes Arch Clin Exp Ophthalmol 1982; 218(1)9–13, [PUBMED], [INFOTRIEVE], [CSA]
- Moorthy R S, Inomata H, Rao N A. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995; 39: 265–291, [PUBMED], [INFOTRIEVE], [CSA]
- Jabs D A, Rosenbaum J T, Foster C S, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492–513, [PUBMED], [INFOTRIEVE], [CSA]
- Belfort Junior R, Nishi M, Hayashi S, et al. Vogt Koyanagi Harada's disease in Brazil. Jpn J Ophthalmol 1988; 32(3)344–347, [PUBMED], [INFOTRIEVE], [CSA]
- Nussenblat R B, Palestine A G, Chan C C. Cyclosporine therapy for uveitis: long term followup. J Ocul Pharmacol 1985; 1(4)369–382, [CSA]
- Vitale A T, Rodriguez A, Foster C S. Low dose cyclosporine A therapy in treating chronic, noninfectious uveitis. Ophthalmology 1996; 103(3)365–374, [PUBMED], [INFOTRIEVE], [CSA]
- Wakatsuki Y, Kogure M, Takahashi Y, Oguro Y. Combination therapy with cyclosporin A and steroid in severe case of Vogt Koyanagi Harada's disease. Jpn J Ophthalmol 1988; 32(3)358–360, [PUBMED], [INFOTRIEVE], [CSA]
- Wakefield D, McCluseky P, Reece G. Cyclosporin therapy in Vogt Koyanagi Harada disease. Aust NZ J Ophthalmol 1990; 18(2)137–142, [CSA]
- Ishioka M, Ohno S, Nakamura S, Isobe K, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994; 118(6)723–729, [PUBMED], [INFOTRIEVE], [CSA]
- Yang P, Wang H, Zhou H, Zhong H, et al. [Therapeutic regimen in Vogt Koyanagi Harada syndrome]. Zhonghua Yan Ke Za Zhi 2002; 38(4)196–199, [PUBMED], [INFOTRIEVE], [CSA]
- Limon S, Girard P, Bloch-Michel E, et al. [Current aspects of the Vogt Koyanagi Harada syndrome]. J Fr Ophtalmol 1985; 8(1)29–35, [PUBMED], [INFOTRIEVE], [CSA]